HUP0201224A2 - Glioblasztóma kezelésére alkalmas rákellenes szert tartalmazó biodegradálható mikrogömbök alkalmazása gyógyszer termék előállítására - Google Patents

Glioblasztóma kezelésére alkalmas rákellenes szert tartalmazó biodegradálható mikrogömbök alkalmazása gyógyszer termék előállítására

Info

Publication number
HUP0201224A2
HUP0201224A2 HU0201224A HUP0201224A HUP0201224A2 HU P0201224 A2 HUP0201224 A2 HU P0201224A2 HU 0201224 A HU0201224 A HU 0201224A HU P0201224 A HUP0201224 A HU P0201224A HU P0201224 A2 HUP0201224 A2 HU P0201224A2
Authority
HU
Hungary
Prior art keywords
biodegradable microspheres
microspheres
anticancer agent
gliobastoma
treating
Prior art date
Application number
HU0201224A
Other languages
English (en)
Inventor
Jean-Pierre Benoit
Nathalie Faisant
Philippe Menei
Original Assignee
Laboratoires Des Produits Ethiques Ethypharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Des Produits Ethiques Ethypharm filed Critical Laboratoires Des Produits Ethiques Ethypharm
Publication of HUP0201224A2 publication Critical patent/HUP0201224A2/hu
Publication of HUP0201224A3 publication Critical patent/HUP0201224A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A találmány tárgya rádioaktív sugárzással szemben szenzibilizálórákellenes szert tartalmazó biodegradálódó mikrogömbök alkalmazásagyógyszertermék előállítására. A találmány szerinti biodegradálódómikrogömbök alkalmazásával a betegek túlélési ideje legalább 90 hét,ezen időtartam alatt a parenchymatikus területen terápiásan hatásoskoncentráció áll fenn. A mikrogömbök előnyösen 5-fluoruracilttartalmaznak 5-(d,l-tejsav-ko-glikolsav) polimerrel bevonva. Amikrogömböket a tumor kimetszése után az operáció helyének falábainjektálják intratisszuláris injekcióval. A tumortömeget célzórádioterápiát körülbelül 6 hétig végzik 60 Gy dózisban. A találmánykiterjed a biodegradálódó mikrogömbök emulziós-extrakciós eljárássaltörténő előállítására és az ilyen eljárással előállítottbiodegradálódó mikrogömböket tartalmazó szuszpenzióra is. Ó
HU0201224A 1999-05-17 2000-05-17 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma HUP0201224A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9906207A FR2793684B1 (fr) 1999-05-17 1999-05-17 Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant

Publications (2)

Publication Number Publication Date
HUP0201224A2 true HUP0201224A2 (hu) 2002-11-28
HUP0201224A3 HUP0201224A3 (en) 2004-05-28

Family

ID=9545636

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201224A HUP0201224A3 (en) 1999-05-17 2000-05-17 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma

Country Status (30)

Country Link
US (2) US6803052B2 (hu)
EP (2) EP1228755A1 (hu)
JP (1) JP5230045B2 (hu)
KR (1) KR100649948B1 (hu)
CN (1) CN1210020C (hu)
AR (1) AR024008A1 (hu)
AT (1) ATE228353T1 (hu)
AU (1) AU775320B2 (hu)
BG (1) BG64936B1 (hu)
BR (1) BR0010648A (hu)
CA (1) CA2388656C (hu)
CZ (1) CZ20014137A3 (hu)
DE (1) DE60000842T2 (hu)
DK (1) DK1053746T3 (hu)
EA (1) EA004943B1 (hu)
ES (1) ES2185544T3 (hu)
FR (1) FR2793684B1 (hu)
HK (1) HK1047044B (hu)
HU (1) HUP0201224A3 (hu)
IL (2) IL146467A0 (hu)
MX (1) MXPA01011919A (hu)
NO (1) NO331686B1 (hu)
NZ (1) NZ515515A (hu)
PL (1) PL201614B1 (hu)
PT (1) PT1053746E (hu)
SI (1) SI1053746T1 (hu)
SK (1) SK16342001A3 (hu)
TW (1) TWI229608B (hu)
WO (1) WO2000069413A1 (hu)
ZA (1) ZA200109415B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7096864B1 (en) 1999-08-05 2006-08-29 Map Medizin-Technologie Gmbh Device for supplying respiratory gas
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
CN1520313A (zh) * 2001-05-23 2004-08-11 ������ҩ��ʽ���� 一种加速骨折愈合的组合物
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
CA2452412C (en) 2001-06-29 2011-05-24 Medgraft Microtech, Inc. Biodegradable injectable implants and related methods of manufacture and use
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US8986737B2 (en) 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
CA3081288C (en) 2003-06-20 2022-10-18 ResMed Pty Ltd Breathable gas apparatus with humidifier
WO2005023293A1 (en) * 2003-09-09 2005-03-17 Pohang University Of Science And Technology Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
CA2560261A1 (en) * 2004-03-18 2005-09-29 St. Luke's Hospital Method for the delivery of sustained release agents
US8088413B2 (en) * 2004-04-16 2012-01-03 Nuvue Therapeutics, Inc. Methods for improved cryo-chemotherapy tissue ablation
JP4929159B2 (ja) 2004-04-16 2012-05-09 ヌーヴ セラピュティクス、インコーポレイテッド 画像誘導組織切除を改善するための装置
JP5221134B2 (ja) 2004-09-07 2013-06-26 バイオコンパティブルズ ユーケー リミテッド 塞栓剤からの薬物送達
US8702580B2 (en) * 2004-10-06 2014-04-22 Brainlab Ag Method and device for assisting in a tissue treatment
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
CN1299685C (zh) * 2005-01-26 2007-02-14 上海大学 氟尿嘧啶载药微球及其制备方法
CN100340297C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 抗癌体内植入剂
CN1923281B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含植物生物碱的抗癌缓释注射剂
CN100464785C (zh) * 2005-08-30 2009-03-04 孔庆忠 一种抗癌药物缓释注射剂及其应用
CN1923282B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含激素类药物的抗癌缓释注射剂
CN1923173B (zh) * 2006-02-24 2010-05-19 济南康泉医药科技有限公司 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂
WO2007105218A2 (en) * 2006-03-14 2007-09-20 Yeda Research And Development Co. Ltd. Composition and method for brain tumor therapy
CN100464736C (zh) * 2006-03-17 2009-03-04 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
HUE052136T2 (hu) 2011-12-13 2021-04-28 Engeneic Molecular Delivery Pty Ltd Bakteriális eredetû intakt minisejtek terápiás szerek agydaganatokba történõ bejuttatására
US10342769B2 (en) * 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
EP3373907A4 (en) * 2015-11-11 2019-12-18 Qrono, Inc. EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
EP4106727A1 (en) 2020-02-18 2022-12-28 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
WO1998016242A1 (en) * 1996-10-16 1998-04-23 Regeneron Pharmaceuticals, Inc. Method of enhancing the delivery of growth factors
WO1998043977A1 (fr) * 1997-03-31 1998-10-08 Toray Industries, Inc. Derives de quinolinomorphinane et leur usage medical
CA2306228A1 (en) * 1997-10-14 1999-04-22 Cambridge Neuroscience, Inc. Therapeutic methods comprising use of a neuregulin

Also Published As

Publication number Publication date
IL146467A0 (en) 2002-07-25
US6803052B2 (en) 2004-10-12
SK16342001A3 (sk) 2002-08-06
KR20020000178A (ko) 2002-01-04
US7041241B2 (en) 2006-05-09
DK1053746T3 (da) 2003-03-31
JP5230045B2 (ja) 2013-07-10
MXPA01011919A (es) 2002-05-06
CZ20014137A3 (cs) 2002-06-12
TWI229608B (en) 2005-03-21
PT1053746E (pt) 2003-04-30
AU775320B2 (en) 2004-07-29
HK1047044B (zh) 2005-12-23
HK1047044A1 (en) 2003-02-07
IL146467A (en) 2006-06-11
AU4764100A (en) 2000-12-05
JP2002544219A (ja) 2002-12-24
ES2185544T3 (es) 2003-05-01
BG106106A (en) 2002-05-31
PL201614B1 (pl) 2009-04-30
NO20015501D0 (no) 2001-11-09
US20030175356A1 (en) 2003-09-18
AR024008A1 (es) 2002-09-04
EA200101206A1 (ru) 2002-04-25
BR0010648A (pt) 2002-02-19
NO331686B1 (no) 2012-02-20
DE60000842T2 (de) 2003-08-28
EP1228755A1 (fr) 2002-08-07
CA2388656A1 (fr) 2000-11-23
NZ515515A (en) 2004-02-27
ZA200109415B (en) 2003-01-29
EA004943B1 (ru) 2004-10-28
BG64936B1 (bg) 2006-10-31
FR2793684A1 (fr) 2000-11-24
US20020051749A1 (en) 2002-05-02
EP1053746B1 (fr) 2002-11-27
HUP0201224A3 (en) 2004-05-28
PL352372A1 (en) 2003-08-25
EP1053746A1 (fr) 2000-11-22
DE60000842D1 (de) 2003-01-09
ATE228353T1 (de) 2002-12-15
CN1210020C (zh) 2005-07-13
KR100649948B1 (ko) 2006-11-24
CA2388656C (fr) 2011-04-26
FR2793684B1 (fr) 2001-08-10
CN1356892A (zh) 2002-07-03
SI1053746T1 (en) 2003-04-30
NO20015501L (no) 2002-01-09
WO2000069413A1 (fr) 2000-11-23

Similar Documents

Publication Publication Date Title
HUP0201224A2 (hu) Glioblasztóma kezelésére alkalmas rákellenes szert tartalmazó biodegradálható mikrogömbök alkalmazása gyógyszer termék előállítására
US6652884B2 (en) Method for the treatment of solid tumors by albumin microparticles incorporating paclitaxel
EP0290891B1 (en) Controlled drug delivery system for treatment of neural disorders
US20050175668A1 (en) Lapachone delivery systems, compositions and uses related thereto
DE69529054T2 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
US5871771A (en) Micronized biodegradable particles, process for preparing them and use thereof
CN109125739A (zh) 多功能高分子胶束药物递送系统及其制备方法和应用
ES469878A1 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento del habito de consumir drogas
US11129894B2 (en) Sensitizing cells to proton radiation
Zhong et al. New Progress in Improving the Delivery Methods of Bisphosphonates in the Treatment of Bone Tumors
US20120035531A1 (en) On-demand and reversible drug release by external cue
US5637085A (en) Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site
EP3275447B1 (en) Gel local anesthetic agent and gel local anesthetic preparation using same
CN1846672A (zh) 一种含抗代谢类药物的抗癌药物组合物
US11541061B2 (en) Neuroblastoma treatment with taurolidine hydrolysis products
CN101879143B (zh) 一种含有抗帕金森病药物的微球组合药物及其应用
CN101879153B (zh) 一种左旋多巴甲酯和苄丝肼混和药物缓释微球组合物及其制备方法
EP3843746A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
Karale et al. Pros and cons of pulsatile drug delivery system
Yakubova et al. S9. 710. Synthesis and application of calcium carbonate nanopar-ticles for combined therapy of oncological diseases
CN101327185A (zh) 一种抗癌缓释植入剂
Byrd et al. Stimulation of trigeminal motoneurons by in vivo implantation of glutamate‐impregnated microspheres
Hincal et al. Biomedical Science and Technology: Recent Developments in the Pharmaceutical and Medical Sciences
US10188601B2 (en) Continuous long-term controlled release of telomerase inhibitors
US8835453B2 (en) Sustained release implant for granisetron

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees